The gut-lung axis rarely gets the clinical attention it deserves, yet for the roughly 7 million people worldwide living with inflammatory bowel disease, the lungs may be a critical and underappreciated target organ. Evidence that IBD drives systemic inflammation beyond the gastrointestinal tract has been building for years, but large-scale, long-term data quantifying pulmonary risk have been largely absent — until now.
Drawing on Sweden's National Patient Register, investigators assembled one of the largest IBD cohorts ever studied for extra-intestinal outcomes: 85,705 individuals diagnosed with IBD between 1969 and 2019, matched against 412,677 general-population comparators and followed for a median of 14 years. Patients with IBD developed interstitial lung disease at an incidence of 34 per 100,000 person-years versus 20 per 100,000 in comparators — translating to a 48% elevated relative risk (HR 1.48; 95% CI 1.30–1.69). Both ulcerative colitis and Crohn's disease independently conferred elevated ILD risk. Critically, a sibling-controlled sub-analysis — which adjusts for shared genetics and early environment — yielded an even stronger association (HR 1.81; 95% CI 1.43–2.27), suggesting the excess risk is not primarily attributable to familial confounders.
These findings deserve attention from gastroenterologists and pulmonologists alike. ILD encompasses a heterogeneous spectrum of fibro-inflammatory lung pathologies, several of which — including cryptogenic organizing pneumonia — have long been recognized as rare extra-intestinal manifestations of IBD. What this study adds is population-scale confirmation that ILD is not merely anecdotal in IBD but a statistically robust, consistently observed complication. One important caveat is that diagnostic codes, while validated in Swedish registers, may misclassify or under-capture early ILD. Additionally, medication confounding — particularly from biologics, immunomodulators, and aminosalicylates — could not be fully disentangled, and some agents used to treat IBD carry their own pulmonary toxicity profiles. Whether the mechanism is shared immune dysregulation, microbiome-driven systemic inflammation, or treatment-related injury remains unresolved. For a health-conscious adult with IBD, this study reinforces why respiratory symptoms warrant prompt specialist evaluation rather than dismissal as unrelated.